An exploratory analysis of the phase 3 MYSTIC trial suggests that the high rate of subsequent post-study immunotherapy received by patients with metastatic non-small cell lung cancer (NSCLC) who previously received chemotherapy, confounded the primary overall survival (OS) outcome. Durvalumab...
Head-to-head comparison of two ALK inhibitors
Brigatinib showed a statistically and clinically relevant improvement in PFS vs crizotinib in patients with anaplastic lymphoma kinase (ALK) inhibitor-naïve, ALK-positive non-small cell lung cancer (NSCLC). This was the result of the first interim analysis from the ALTA-1L study comparing the...